Israeli generic major Teva and Mumbai-based Glenmark Pharmaceuticals have settled a patent dispute over various generic versions of Coreg — a drug used for treating congestive heart failure — out of court. Teva had filed a case against Glenmark Generics (Glenmark Pharma’s US subsidiary) over the latter’s process patent for preparing Carvedilol, the main pharmaceutical compound used in the generic version of Coreg. Glenmark had, in turn, filed a lawsuit challenging two of Teva’s patents related to the drug.
Teva, which filed its case in August 2008, claimed that Glenmark was not using a novel method to make the drug, and had instead infringed on a process which the Israeli firm had patented. Glenmark contended that it had an innovative process for manufacturing the drug.
In December 2008, the Indian company filed a set of counter-claims calling Teva’s patents invalid and unenforceable due to misrepresentation to the US Patent and Trademark Office. It also accused Teva of engaging in “sham” litigation and violating federal antitrust laws
Glenmark is not the only company that Teva had filed a lawsuit regarding this product. The Israeli firm had filed lawsuits against seven Indian companies related to Carvedilol. Ranbaxy and Dr Reddy’s had already settled out of court with Teva.